Replies to post #10245 on Biotech Values

[poorgradstudent]

So you say Pazdur may be bad news for DNDN, walldiver thinks it may be good news.

One of you is loco.

;-)

The Pazdur giant appears to be engulfing more and more of the FDA.

[Biowatch]

>>He has the power to stack ODAC committees with an inordinate number of biostatistician voters.<<

I wouldn't say that he stacks the ODAC with statisticians. There are typically 10 to 15 people on an advisory panel, with only one or two statisticians, but he certainly has the ability to chill an audience in a general meeting (e.g., one on surrogate endpoints) by calling out the person's name and company as they approach the microphone to ask a question.

Is DNDN going up for an ODAC review? If so, when?

P.S., A link describing Advisory Committees:
http://www.fda.gov/fdac/features/2004/104_adv.html

and transcripts of meetings:
http://www.fda.gov/ohrms/dockets/ac/acmenu.htm